# US 8,278,100 B2 · Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,100 B2
- Document ID: US8278100B2
- Status: Granted
- Kind: B2
- Application number: 12/462,005
- Filed: 2009-07-28
- Published: 2010-02-18
- Granted: 2012-10-02
- Earliest claimed: 2008-07-28
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Yves Pommier; Yongwei Zhang; Arun K. Ghosh
- Web page: https://patentgrep.com/patent/US8278100B2

## CPC

- C07D 493/18: Bridged systems
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative.

## Claims

### Claim 1

A method of stimulating chromosome condensation in a cell, and observing chromosome condensation in the cell, wherein chromosome condensation is observed by a chromosome spread assay, a DNase I sensitivity assay, a phosphatase activity assay, an immunofluorescence assay, a cell adhesion assay, or a transwell migration assay;
and the compound is chosen from

### Claim 2 (depends on 1)

The method of claim 1 wherein the chromosome condensation is observed by a phosphatase activity assay, an immunofluorescence assay, a cell adhesion assay, or a transwell migration assay.

### Claim 3 (depends on 1)

The method of claim 1 wherein the cells are contacted in vitro.

### Claim 4 (depends on 3)

The method of claim 3 wherein the cells are proliferating cells; and the concentration of the compound is from about 1 nM to about 100 nM.

### Claim 5 (depends on 1)

The method of claim 1 wherein the cells are proliferating cells, the cells are contacted in vivo by administering the compound to a subject; and the Cmax of the compound of formula (I) is at least 1 nM.

### Claim 6

A method of analyzing human cell chromosomes by causing premature chromosome condensation, which comprises:
(a) incubating a cell in vitro with a medium comprising a lasonolide derivative chosen from
wherein the lasonolide derivative is present in an amount effective to induce premature chromosome condensation
(b) analyzing the chromosomes treated in step a);
wherein analyzing the chromosome comprises preparing a chromosome spread of the treated chromosomes; or
hybridizing a detectable oligonucleotide to at least one or more chromosomes and enumerating chromosome spots.

### Claim 7 (depends on 6)

The method of claim 6 wherein the detectable oligonucleotide is an oligonucleotide bound to a fluorescent moiety or bound to a moiety selected from a group consisting of biotin, digoxigenin, antigens, enzymes and haptens.

### Claim 8

A culture medium for inducing premature chromosome condensation in a cell comprising a lasonolide derivative having mitosis enhancing properties present in an amount effective to induce premature chromosome condensation; wherein the lasonolide derivative is a selected from
further comprising a phosphatase inhibitor selected from a group consisting of okadaic acid, salts of okadaic acid, calyculin A, cantharidic acid, cantharidin, cypermethrin, deltamethrin, dephostatin, 3,4-dephostatin, endothall, fenvalerate, fostriecin, microcystin-LA, microcystin-LF, microcystin-LR, microcystin-LW, microcyctin-RR, and microcystin-YR.
